<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02512978</url>
  </required_header>
  <id_info>
    <org_study_id>Z15110700400000</org_study_id>
    <nct_id>NCT02512978</nct_id>
  </id_info>
  <brief_title>Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction(ThyroHeart-AMI)</brief_title>
  <official_title>Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Municipal Science &amp; Technology Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Luhe Teaching Hospital of the Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on accumulating evidences showing that hypothyroid status is associated with poor
      prognosis among acute myocardial infarction (AMI) patients, the study is designed to evaluate
      whether replacement treatment with levothyroxine could have beneficial effects on patients
      with AMI and hypothyroidism. This is a multicenter prospective computerized-randomized trial
      stratified by ejection fraction with a 1:1 ratio to levothyroxine group or standard therapy
      group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary hypothesis is that reversing the hypothyroid status with levothyroxine on top of
      standard therapy for AMI is safe and has beneficial effects on cardiac function, myocardial
      perfusion/metabolism and myocardial fibrosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The improvement of Left Ventricular ejection fraction assessed by cardiac magnetic resonance imaging</measure>
    <time_frame>within 6 months of patient enrolled</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial perfusion and metabolism detected by 99Tcm-MIBI SPECT and 18F-FDG PET imaging</measure>
    <time_frame>Within 6 months of patient enrolled</time_frame>
    <description>Patterns of myocardial perfusion/metabolism were classified as normal, mismatch, mild-moderate match and severe match</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severity of myocardial fibrosis assessed by late-gadolinium enhancement cardiac magnetic resonance imaging(cMRI-LGE)</measure>
    <time_frame>Within 6 months of patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac and cerebrovascular events</measure>
    <time_frame>within 12 months of patient enrolled</time_frame>
    <description>The composite endpoint of cardiac death, myocardial infarction, target vessel revascularization and cerebrovascular accident.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death by any cause</measure>
    <time_frame>Within 12 months of patient enrolled</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Hypothyroidism</condition>
  <arm_group>
    <arm_group_label>Levothyroxine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients in this group receive standard therapy in consistent with the local clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine</intervention_name>
    <description>Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.</description>
    <arm_group_label>Levothyroxine group</arm_group_label>
    <other_name>Euthyrox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 - 75, male or non-pregnant female;

          2. Is diagnosed acute myocardial infarction and received primary percutaneous coronary
             intervention (PCI);

          3. With presence of hypothyroid status (i.e., TSH &gt;7.0 mIU/L and (or) fT3 &lt;1.79 pg/mL);

          4. Is able to understand the objective of the trial, takes part voluntarily and signs the
             written informed consent form.

        Exclusion Criteria:

          1. Those who have participated in other drug or therapeutic equipment clinical trials but
             do not reach the main study endpoint time limit;

          2. Symptoms of severe heart failure (Killip Class III and above);

          3. Severely impaired renal function before surgery: serum creatinine &gt; 2.0mg/dl;

          4. Impaired liver function before surgery: Serum GPT &gt; 120U/L;

          5. Those who have prior thyroid diseases and already on levothyroxine or anti-thyroid
             medicines;

          6. Those taking medicine which can affect the test of thyroid function;

          7. Patients who plan to undergo coronary artery bypass grafting or other surgery within 3
             months;

          8. Those having prior myocardial infarction;

          9. Patients who are deemed by the researchers to have low compliance and unable to abide
             by the requirements and complete the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Da Tang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wen-Yao Wang, MD,PhD Candidate</last_name>
    <phone>8618810488381</phone>
    <phone_ext>861088396171</phone_ext>
    <email>wwypumc@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Chen, MD</last_name>
    <phone>8618618285284</phone>
    <phone_ext>861088396171</phone_ext>
    <email>tyler_1985@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fuwai Cardiovascular Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuo Zhang, MD,PhD Candidant</last_name>
      <phone>+86 18813019602</phone>
      <email>zk1989y@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/heartattack.html</url>
    <description>heart attack</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/hypothyroidism.html</url>
    <description>hypothyroidism</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682461.html</url>
    <description>levothyroxine</description>
  </link>
  <results_reference>
    <citation>Li J, Li X, Wang Q, Hu S, Wang Y, Masoudi FA, Spertus JA, Krumholz HM, Jiang L; China PEACE Collaborative Group. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet. 2015 Jan 31;385(9966):441-51. doi: 10.1016/S0140-6736(14)60921-1. Epub 2014 Jun 23. Retraction in: Lancet. 2015 Jan 31;385(9966):402.</citation>
    <PMID>24969506</PMID>
  </results_reference>
  <results_reference>
    <citation>Pingitore A, Chen Y, Gerdes AM, Iervasi G. Acute myocardial infarction and thyroid function: new pathophysiological and therapeutic perspectives. Ann Med. 2012 Dec;44(8):745-57. doi: 10.3109/07853890.2011.573501. Epub 2011 May 13. Review.</citation>
    <PMID>21568669</PMID>
  </results_reference>
  <results_reference>
    <citation>Mourouzis I, Forini F, Pantos C, Iervasi G. Thyroid hormone and cardiac disease: from basic concepts to clinical application. J Thyroid Res. 2011;2011:958626. doi: 10.4061/2011/958626. Epub 2011 Jun 19.</citation>
    <PMID>21765997</PMID>
  </results_reference>
  <results_reference>
    <citation>Cakar M, Demirbas S, Demirkol S, Karaman M, Balta S, Unlu M. Chicken or egg? Which one is first? Myocardial infarction or low thyroid hormones? Intern Med. 2013;52(5):645. Epub 2013 Mar 1.</citation>
    <PMID>23448784</PMID>
  </results_reference>
  <results_reference>
    <citation>Ceremuzyński L, Górecki A, Czerwosz L, Chamiec T, Bartoszewicz Z, Herbaczyńska-Cedro K. Low serum triiodothyronine in acute myocardial infarction indicates major heart injury. Kardiol Pol. 2004 May;60(5):468-80; discussion 473-4. English, Polish.</citation>
    <PMID>15247962</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen YF, Kobayashi S, Chen J, Redetzke RA, Said S, Liang Q, Gerdes AM. Short term triiodo-L-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats. J Mol Cell Cardiol. 2008 Jan;44(1):180-7. Epub 2007 Oct 26.</citation>
    <PMID>17964598</PMID>
  </results_reference>
  <results_reference>
    <citation>Bai MF, Gao CY, Yang CK, Wang XP, Liu J, Qi DT, Zhang Y, Hao PY, Li MW. Effects of thyroid dysfunction on the severity of coronary artery lesions and its prognosis. J Cardiol. 2014 Dec;64(6):496-500. doi: 10.1016/j.jjcc.2014.03.009. Epub 2014 Jun 17.</citation>
    <PMID>24951271</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang WY, Tang YD, Yang M, Cui C, Mu M, Qian J, Yang YJ. Free triiodothyronine level indicates the degree of myocardial injury in patients with acute ST-elevation myocardial infarction. Chin Med J (Engl). 2013 Oct;126(20):3926-9.</citation>
    <PMID>24157158</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang B, Peng W, Wang C, Li W, Xu Y. A low fT3 level as a prognostic marker in patients with acute myocardial infarctions. Intern Med. 2012;51(21):3009-15. Epub 2012 Nov 1.</citation>
    <PMID>23124142</PMID>
  </results_reference>
  <results_reference>
    <citation>Mourouzis I, Giagourta I, Galanopoulos G, Mantzouratou P, Kostakou E, Kokkinos AD, Tentolouris N, Pantos C. Thyroid hormone improves the mechanical performance of the post-infarcted diabetic myocardium: a response associated with up-regulation of Akt/mTOR and AMPK activation. Metabolism. 2013 Oct;62(10):1387-93. doi: 10.1016/j.metabol.2013.05.008. Epub 2013 Jun 15.</citation>
    <PMID>23773982</PMID>
  </results_reference>
  <results_reference>
    <citation>Mourouzis I, Mantzouratou P, Galanopoulos G, Kostakou E, Roukounakis N, Kokkinos AD, Cokkinos DV, Pantos C. Dose-dependent effects of thyroid hormone on post-ischemic cardiac performance: potential involvement of Akt and ERK signalings. Mol Cell Biochem. 2012 Apr;363(1-2):235-43. doi: 10.1007/s11010-011-1175-9. Epub 2011 Dec 2.</citation>
    <PMID>22134702</PMID>
  </results_reference>
  <results_reference>
    <citation>Tang YD, Kuzman JA, Said S, Anderson BE, Wang X, Gerdes AM. Low thyroid function leads to cardiac atrophy with chamber dilatation, impaired myocardial blood flow, loss of arterioles, and severe systolic dysfunction. Circulation. 2005 Nov 15;112(20):3122-30. Epub 2005 Nov 7.</citation>
    <PMID>16275864</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2015</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Yi-Da Tang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>myocardial infarction</keyword>
  <keyword>hypothyroidism</keyword>
  <keyword>levothyroxine</keyword>
  <keyword>cardiac magnetic resonance imaging</keyword>
  <keyword>myocardial perfusion/metabolism radionuclide imaging</keyword>
  <keyword>myocardial fibrosis</keyword>
  <keyword>myocardial perfusion/metabolism</keyword>
  <keyword>cardiac function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

